Euroapi SA Ownership
| EAPIF Stock | USD 2.63 0.84 24.21% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Euroapi |
Euroapi Pink Sheet Ownership Analysis
About 42.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. Euroapi SA had not issued any dividends in recent years. Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France. Euroapi Sa is traded on OTC Exchange in the United States.The quote for Euroapi SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Euroapi SA call Karl Rotthier at 33 1 89 20 62 00 or check out https://www.euroapi.com/en.Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Euroapi Pink Sheet
Euroapi SA financial ratios help investors to determine whether Euroapi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Euroapi with respect to the benefits of owning Euroapi SA security.